# US 9,517,307 B2 · Devices and methods for delivering opioid antagonists including formulations for naloxone > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,517,307 B2 - Document ID: US9517307B2 - Status: Granted - Kind: B2 - Application number: 14/335,490 - Filed: 2014-07-18 - Published: 2016-01-21 - Granted: 2016-12-13 - Earliest claimed: 2014-07-18 - Assignees: kaleo, Inc. - Applicants: kaleo, Inc. - Inventors: Frank E. Blondino; Eric S. Edwards; Evan T. Edwards; Glen L. Kelley; Paul F. Meyers - Web page: https://patentgrep.com/patent/US9517307B2 ## CPC - A61M 5/3234: {Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 31/485: Morphinan derivatives, e.g. morphine, codeine - A61M 5/2033: {Spring-loaded one-shot injectors with or without automatic needle insertion (multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287)} - A61M 5/2053: {Media being expelled from injector by pressurised fluid or vacuum (for infusion A61M5/145, A61M5/155)} - A61M 5/3287: {Accessories for bringing the needle into the body; Automatic needle insertion (A61M5/20, A61M5/31525 take precedence)} - A61M 11/02: operated by air {or other gas} pressure applied to the liquid {or other product} to be sprayed or atomised {(sprayers for horticulture A01G, A01H; killing insects A01M; air humidifying by nozzles F24F6/14, F24F6/18; cooling by spraying F28B, F28C)} - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract An apparatus includes a container, a needle, and an actuation assembly. The container contains a dose of a naloxone composition having a delivered volume of at least about 0.34 mL. The actuation assembly includes an energy storage member that produces a force on a movable member to move the needle and to deliver the dose of the naloxone composition. The 90% confidence interval of at least one of the relative mean maximum naloxone plasma concentration after dose delivery into the body (Cmax), time to reach the maximum naloxone plasma concentration (Tmax), area under the plasma concentration-time curve from pre-dose (time 0) extrapolated to infinity (AUC0-∞), or area under the plasma concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (Tlast) (AUC0-t) of the delivered dose to a delivered dose of a corresponding naloxone composition delivered via a manually-actuated syringe is within 80% to 125%. ## Claims ### Claim 1 An apparatus, comprising: a housing; a medicament container disposed within the housing, the medicament container containing a dose of a naloxone composition, the dose having a delivered volume of at least 0.34 ml; a needle configured to move between a first needle position, in which the needle is disposed within the housing, and a second needle position, in which a portion of the needle extends from the housing, the needle configured to be placed in fluid communication with the medicament container when the needle is in the second needle position; and an actuation assembly including an energy storage member and a movable member, the energy storage member configured to produce a force on the movable member to move the needle from the first needle position to the second needle position and deliver the dose of the naloxone composition from the medicament container via the needle, when actuated, the actuation assembly delivers the dose of the naloxone composition into a body in less than 0.5 seconds and such that a 90% confidence interval of at least one of a relative mean maximum naloxone plasma concentration after the dose is delivered into the body (Cmax), a time to reach a maximum naloxone plasma concentration (Tmax), an area under a plasma concentration-time curve from pre-dose (time 0) extrapolated to infinity (AUC0-∞), or an area under a plasma concentration-time curve from pre-dose (time 0) to a time of a last quantifiable concentration (Tlast) (AUC0-t) of the delivered dose to a delivered dose of a corresponding naloxone composition delivered via a manually-actuated syringe is within 80% to 125%. ### Claim 2 (depends on 1) The apparatus of claim 1, wherein the force delivered by the actuation assembly on the movable member decreases during delivery of the dose from a start force to an end force. ### Claim 3 (depends on 1) The apparatus of claim 1, wherein the force delivered by the actuation assembly on the movable member decreases during delivery of the dose from a start force to an end force, the start force being between 30 pounds and 38 pounds, the end force being between 23 pounds and 31 pounds. ### Claim 4 (depends on 1) The apparatus of claim 1, wherein when the actuation assembly is actuated, a pressure produced within the medicament container by the movable member decreases during delivery of the dose from a start pressure to an end pressure, the start pressure being between 525 pounds per square inch and 670 pounds per square inch, the end pressure being between 400 pounds per square inch and 545 pounds per square inch. ### Claim 5 (depends on 1) The apparatus of claim 1, further comprising: a retraction mechanism configured to produce a retraction force to move the needle from the second needle position towards the first needle position after delivery of the dose. ### Claim 6 (depends on 1) The apparatus of claim 1, further comprising: a retraction mechanism configured to produce a retraction force of 5 pounds to move the needle from the second needle position towards the first needle position after delivery of the dose. ### Claim 7 (depends on 1) The apparatus of claim 1, further comprising: a retraction spring configured to urge the needle towards the first needle position; and a release member, the movable member configured to interface with the release member after delivery of the dose to release the force from the movable member, the actuation assembly and the release member configured such that 0.4 ml of the naloxone composition is delivered before the needle begins movement from the second needle position towards the first needle position. ### Claim 8 (depends on 1) The apparatus of claim 1, wherein the delivered volume is 0.4 ml. ### Claim 9 (depends on 1) The apparatus of claim 1, wherein the delivered volume is between 0.34 ml and 0.46 ml. ### Claim 10 (depends on 1) The apparatus of claim 1, wherein the delivered volume is between 0.34 ml and 2 ml. ### Claim 11 (depends on 1) The apparatus of claim 1, wherein the amount of the dose is 0.4 mg. ### Claim 12 (depends on 1) The apparatus of claim 1, wherein the amount of the dose is between 0.4 mg and 1 mg. ### Claim 13 (depends on 1) The apparatus of claim 1, wherein the amount of the dose is between 0.4 mg and 2 mg. ### Claim 14 (depends on 1) The apparatus of claim 1, wherein the amount of the dose is between 0.4 mg and 10 mg. ### Claim 15 (depends on 1) The apparatus of claim 1, wherein the energy storage member is a compressed gas container having an initial container pressure of 1100 pounds per square inch. ### Claim 16 (depends on 1) The apparatus of claim 1, wherein when actuated, the actuation assembly delivers the dose of the naloxone composition into the body such that the 90% confidence interval of the relative mean Cmax of a delivered dose to the delivered dose of the corresponding naloxone composition delivered via the manually-actuated syringe is within 100% to 125%. ### Claim 17 (depends on 1) The apparatus of claim 1, wherein the needle has an exposed needle length of 0.5 between 0.49 inches and 0.51 inches when the needle is in the second needle position. ### Claim 18 A method, comprising: placing a medicament injector against a body, the medicament injector including: a housing; a medicament container disposed within the housing, the medicament container containing a dose of a naloxone composition, the dose having a delivered volume of at least 0.34 ml; a needle configured to move between a first needle position and a second needle position, a portion of the needle extending from the housing when the needle is in the second needle position, the needle configured to be placed in fluid communication with the medicament container when the needle is in the second needle position; and an actuation assembly including an energy storage member and a movable member; and actuating the medicament injector such that the energy storage member produces a force on the movable member to move the needle from the first needle position to the second needle position and deliver the dose of the naloxone composition from the medicament container via the needle into the body in less than 0.5 seconds and in a manner such that a 90% confidence interval of at least one of a relative mean maximum naloxone plasma concentration after the dose is delivered into the body (Cmax), a time to reach a maximum naloxone plasma concentration (Tmax), an area under a plasma concentration-time curve from pre-dose (time 0) extrapolated to infinity (AUC0-∞), or an area under the plasma concentration-time curve from pre-dose (time 0) to a time of a last quantifiable concentration (Tlast) (AUC0-t) of the delivered dose to a delivered dose of a corresponding naloxone composition delivered via a manually-actuated syringe is within 80% to 125%. ### Claim 19 (depends on 18) The method of claim 18, wherein the actuating includes pressing a distal end portion of the housing against the body. ### Claim 20 (depends on 18) The method of claim 18, wherein the portion of the needle has a length of 0.5 between 0.49 inches and 0.51 inches.